KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Precigen (PGEN) EBITDA (2016 - 2025)

Precigen (PGEN) has disclosed EBITDA for 14 consecutive years, with -$34.5 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 62.17% to -$34.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$117.4 million, a 16.61% increase, with the full-year FY2024 number at -$135.0 million, down 35.36% from a year prior.
  • EBITDA was -$34.5 million for Q3 2025 at Precigen, down from -$31.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$7.6 million in Q3 2022 to a low of -$60.8 million in Q2 2024.
  • A 5-year average of -$26.2 million and a median of -$23.5 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 193.57% in 2021, then skyrocketed 64.64% in 2022.
  • Precigen's EBITDA stood at -$33.1 million in 2021, then surged by 34.18% to -$21.8 million in 2022, then plummeted by 57.01% to -$34.2 million in 2023, then rose by 16.68% to -$28.5 million in 2024, then decreased by 20.92% to -$34.5 million in 2025.
  • Per Business Quant, the three most recent readings for PGEN's EBITDA are -$34.5 million (Q3 2025), -$31.8 million (Q2 2025), and -$22.6 million (Q1 2025).